These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
¨
|
|
Preliminary Proxy Statement
|
|
|
|
¨
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a- 6(e)(2) )
|
|
|
|
ý
|
|
Definitive Proxy Statement
|
|
|
|
¨
|
|
Definitive Additional Materials
|
|
|
|
¨
|
|
Soliciting Material Pursuant to §240.14a-12
|
ý
|
|
No fee required.
|
|||
¨
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|||
|
|
(1
|
)
|
|
Title of each class of securities to which transaction applies:
|
|
|
(2
|
)
|
|
Aggregate number of securities to which transaction applies:
|
|
|
(3
|
)
|
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
(4
|
)
|
|
Proposed maximum aggregate value of transaction:
|
|
|
(5
|
)
|
|
Total fee paid:
|
¨
|
|
Fee paid previously with preliminary materials.
|
|||
¨
|
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
|
|||
|
|
(1
|
)
|
|
Amount Previously Paid:
|
|
|
(2
|
)
|
|
Form, Schedule or Registration Statement No.:
|
|
|
(3
|
)
|
|
Filing Party:
|
|
|
(4
|
)
|
|
Date Filed:
|
|
Sincerely,
|
|
|
Dr. Valentin P. Gapontsev
Chairman of the Board of Directors and
Chief Executive Officer
|
|
|
|
Page
|
Notice of Annual Meeting of Stockholders
|
|
General Information About the Meeting
|
|
Corporate Governance
|
|
Related Person Transactions
|
|
Board of Directors
|
|
Director Compensation
|
|
Common Stock Ownership
|
|
Proposal 1: Election of Directors
|
|
Executive Officers
|
|
Compensation Committee Report
|
|
Compensation Discussion and Analysis
|
|
Executive Compensation Tables
|
|
Equity Compensation Plans
|
|
Proposal 2: Advisory Vote on Executive Compensation
|
|
Audit Committee Report
|
|
Proposal 3: Ratification of Independent Registered Public Accounting Firm
|
|
Other Matters
|
|
|
|
|
|
|
|
|
|
Date:
|
|
|
|
June 3, 2014
|
|
|
Time:
|
|
|
|
10:00 a.m. Eastern Time
|
|
|
Location:
|
|
|
|
IPG Photonics Corporation
50 Old Webster Road
Oxford, Massachusetts 01540
|
•
|
elect ten directors named in the proxy to serve until our 2015 annual meeting of stockholders;
|
•
|
approve our executive compensation in an advisory vote; and
|
•
|
ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for 2014.
|
|
By order of the Board of Directors
IPG PHOTONICS CORPORATION
|
|
|
Angelo P. Lopresti
Senior Vice President, General Counsel and Secretary
|
When:
|
|
Tuesday, June 3, 2014, at 10:00 a.m. Eastern Time
|
Where:
|
|
IPG Photonics Corporation
50 Old Webster Road
Oxford, Massachusetts 01540
|
•
|
via the Internet;
|
•
|
using a toll-free telephone number;
|
•
|
completing a proxy/voting instruction card and mailing it in the postage-paid envelope provided; or
|
•
|
in person at the meeting.
|
•
|
Independent Director Majority and Presiding Independent Director
. Six of the nine directors currently on our Board of Directors (the “Board”) are non-employees of the Company who meet the independence criteria under applicable rules of the Securities and Exchange Commission ("SEC") and NASDAQ guidelines. Only independent directors sit on our three standing Board committees. Several years ago, the Board established the role of a presiding independent director who is elected annually by the independent directors. More information about the role of the independent directors, the Presiding Independent Director and our Board structure can be found below in this section.
|
•
|
Executive Sessions.
Our Board meets regularly in executive sessions without the presence of management, including our Chairman. These sessions are led by our Presiding Independent Director, as described below in this section.
|
•
|
Annual Election of Entire Board.
Stockholders elect each director annually. We do not have a classified board.
|
•
|
Related Person Transaction Policy.
Our Nominating and Corporate Governance Committee is responsible for approving or ratifying transactions involving our Company and related persons and determining if the transaction is in, or not inconsistent with, the best interests of our Company and our stockholders. More information about our Related Person Transaction Policy and transactions can be found below in this section.
|
•
|
Stock Ownership Guidelines.
Our directors and executive officers are required to own a minimum amount of IPG Photonics shares. We believe that stock ownership requirements align the interest of the directors and officers with our stockholders. Our directors and executive officers fully complied with our guidelines in 2013. In 2013, our Board increased the stock ownership requirements for our directors.
|
•
|
Prohibition on Hedging; Limits on Pledging.
Our Insider Trading Policy expressly prohibits directors and employees from engaging in short sales of our common stock or buying or selling puts, calls or derivative securities in connection with IPG Photonics shares. In 2013, the Board adopted a policy to limit the pledging of our stock by directors and officers.
|
•
|
a majority of our Board must be independent;
|
•
|
the Presiding Independent Director presides over executive sessions of independent directors;
|
•
|
the Board appoints all members and chairpersons of the Board committees;
|
•
|
the Audit, Compensation, and Nominating and Corporate Governance Committees consist solely of independent directors;
|
•
|
the independent directors meet periodically in executive sessions without the presence of the non-independent directors or members of our management;
|
•
|
directors may not serve on the boards of more than three other public companies;
|
•
|
evaluations of the Board and committees are conducted annually; and
|
•
|
the Board and key officers should have a meaningful financial stake in the Company.
|
Name
|
|
Age
|
|
Position
|
Valentin P. Gapontsev, Ph.D.
|
|
75
|
|
Chief Executive Officer and Chairman of the Board
|
Eugene Scherbakov, Ph.D.
|
|
66
|
|
Managing Director of IPG Laser GmbH, Senior Vice President, Europe and Director
|
Igor Samartsev
|
|
51
|
|
Chief Technology Officer and Director
|
Robert A. Blair
|
|
67
|
|
Director
|
Michael C. Child
|
|
59
|
|
Director
|
Henry E. Gauthier
|
|
73
|
|
Director
|
William S. Hurley
|
|
69
|
|
Director
|
Eric Meurice
|
|
57
|
|
Nominee for Director
|
John R. Peeler
|
|
59
|
|
Director
|
Thomas J. Seifert
|
|
50
|
|
Nominee for Director
|
|
|
Board of
Directors
|
|
Audit
|
|
Compensation
|
|
Nominating
and
Corporate
Governance
|
Meetings held in 2013
|
|
5
|
|
7
|
|
11
|
|
8
|
Written consents in 2013
|
|
3
|
|
—
|
|
—
|
|
1
|
Valentin P. Gapontsev, Ph.D.
|
|
Chair
|
|
|
|
|
|
|
Robert A. Blair
|
|
Member
|
|
|
|
Chair
|
|
Member
|
Michael C. Child
|
|
Member
|
|
Member
|
|
|
|
Chair
|
Henry E. Gauthier
|
|
Member, and Presiding
Independent Director
|
|
Member
|
|
|
|
|
William S. Hurley
|
|
Member
|
|
Chair
|
|
Member
|
|
|
William F. Krupke, Ph.D.
|
|
Member
|
|
|
|
|
|
Member
|
John R. Peeler
|
|
Member
|
|
|
|
Member
|
|
Member
|
Igor Samartsev
|
|
Member
|
|
|
|
|
|
|
Eugene Scherbakov, Ph.D.
|
|
Member
|
|
|
|
|
|
|
•
|
reviewing and approving the Chairman and Chief Executive Officer’s compensation based on the annual evaluation of his or her performance with input from the independent directors;
|
•
|
establishing the corporate goals and objectives relevant to the Chairman and Chief Executive Officer and his performance bonus. From 2014, the independent directors will establish and oversee these corporate goals and objectives and provide the evaluation to the Compensation Committee which retains responsibility for determining the performance bonus of the Chairman and Chief Executive Officer;
|
•
|
reviewing and approving compensation decisions recommended by the Chairman and Chief Executive Officer for the other executive officers, including setting base salaries, annual performance bonuses, long-term incentive awards, severance benefits and perquisites;
|
•
|
setting our compensation philosophy and composition of the group of peer companies used for comparison of executive compensation; and
|
•
|
reviewing, and recommending for approval by the Board, the compensation for the non-employee directors.
|
|
Amount
|
||
Board Retainer
|
$
|
40,000
|
|
Presiding Independent Director Retainer
|
$
|
20,000
|
|
Audit Committee Retainers
|
|
||
Chair
|
$
|
22,500
|
|
Non-Chair
|
$
|
10,000
|
|
Compensation Committee Retainers
|
|
||
Chair
|
$
|
20,000
|
|
Non-Chair
|
$
|
7,500
|
|
Nominating and Corporate Governance Committee Retainers
|
|
||
Chair
|
$
|
12,500
|
|
Non-Chair
|
$
|
5,000
|
|
Name
|
|
Fees Earned
or Paid in
Cash ($)
|
|
Stock
Awards
($)(1)
|
|
Option
Awards
($)(1)
|
|
Total ($)
|
||||
Robert A. Blair
|
|
65,000
|
|
|
66,000
|
|
|
166,588
|
|
|
297,588
|
|
Michael C. Child
|
|
62,500
|
|
|
66,000
|
|
|
166,588
|
|
|
295,088
|
|
Henry E. Gauthier
|
|
70,000
|
|
|
99,000
|
|
|
249,882
|
|
|
418,882
|
|
William S. Hurley
|
|
70,000
|
|
|
66,000
|
|
|
166,588
|
|
|
302,588
|
|
William F. Krupke, Ph.D.
|
|
42,500
|
|
|
66,000
|
|
|
166,588
|
|
|
275,088
|
|
John R. Peeler
|
|
50,787
|
|
|
66,000
|
|
|
166,588
|
|
|
283,375
|
|
(1)
|
Valuation based on the fair value of the restricted stock unit and stock option awards as of the grant date determined pursuant to Financial Accounting Standards Board Accounting Standards Codification Topic 718 (“ASC Topic 718”) with respect to 2013. The assumptions that we used with respect to the valuation of restricted stock unit and stock option awards are set forth in Note 2 to our Consolidated Financial Statements in our Annual Report on Form 10-K filed with the SEC on February 28, 2014. On June 4, 2013, each director then serving on the Board was granted restricted stock units for 1,100 shares of common stock and options to purchase 6,500 shares of common stock at an exercise price of
$60.00
per share. Mr. Gauthier, the Presiding Independent Director, was granted on the same day additional restricted stock units for 550 shares of common stock and additional options to purchase 3,250 shares of common stock at an exercise price of
$60.00
per share. Both restricted stock units and options vest in a single installment on June 3, 2014.
|
Name
|
|
Unvested
Restricted
Stock Units
(#)
|
|
Total Option
Awards
Held
(#)
|
|
Exercisable
Option
Awards
(#)
|
|||
Robert A. Blair
|
|
1,100
|
|
|
19,834
|
|
|
13,334
|
|
Michael C. Child
|
|
1,100
|
|
|
43,168
|
|
|
36,668
|
|
Henry E. Gauthier
|
|
1,650
|
|
|
44,752
|
|
|
25,002
|
|
William S. Hurley
|
|
1,100
|
|
|
39,835
|
|
|
33,335
|
|
William F. Krupke, Ph.D.
|
|
1,100
|
|
|
19,834
|
|
|
13,334
|
|
John R. Peeler
|
|
1,100
|
|
|
31,500
|
|
|
6,250
|
|
•
|
each person or entity known by us to own beneficially more than five percent of our common stock;
|
•
|
each of the Named Executive Officers;
|
•
|
each person who is a director or nominee; and
|
•
|
all of our executive officers and directors as a group.
|
Name
|
|
Shares
Owned
|
|
Right to
Acquire
Shares within
60 Days
|
|
Total
|
|
Percent
|
||||
The Valentin Gapontsev Trust I (1)
|
|
15,094,668
|
|
|
—
|
|
|
15,094,668
|
|
|
29.0
|
%
|
Valentin P. Gapontsev, Ph.D. (2)
|
|
7,821,933
|
|
|
—
|
|
|
7,821,933
|
|
|
15.0
|
%
|
IP Fibre Devices (UK) Ltd.
|
|
7,266,002
|
|
|
—
|
|
|
7,266,002
|
|
|
14.0
|
%
|
Artisan Partners Limited Partnership (3)
|
|
3,892,196
|
|
|
—
|
|
|
3,892,196
|
|
|
7.5
|
%
|
Columbia Wanger Asset Management, LLC (4)
|
|
2,595,550
|
|
|
—
|
|
|
2,595,550
|
|
|
5.0
|
%
|
T. Rowe Price Associates, Inc. (5)
|
|
3,190,830
|
|
|
—
|
|
|
3,190,830
|
|
|
6.1
|
%
|
Robert A. Blair
|
|
35,538
|
|
|
13,334
|
|
|
48,872
|
|
|
*%
|
|
Michael C. Child
|
|
8,912
|
|
|
36,668
|
|
|
45,580
|
|
|
*%
|
|
Henry E. Gauthier
|
|
13,000
|
|
|
35,002
|
|
|
48,002
|
|
|
*%
|
|
William S. Hurley
|
|
8,667
|
|
|
33,335
|
|
|
42,002
|
|
|
*%
|
|
William F. Krupke, Ph.D.
|
|
11,700
|
|
|
13,334
|
|
|
25,034
|
|
|
*%
|
|
Eric Meurice
|
|
—
|
|
|
—
|
|
|
—
|
|
|
*%
|
|
John R. Peeler
|
|
—
|
|
|
9,375
|
|
|
9,375
|
|
|
*%
|
|
Igor Samartsev (6)(7)
|
|
905,460
|
|
|
36,875
|
|
|
942,335
|
|
|
1.8
|
%
|
Eugene Scherbakov, Ph.D. (6)(8)
|
|
17,065,235
|
|
|
9,313
|
|
|
17,074,548
|
|
|
32.8
|
%
|
Thomas J. Seifert
|
|
—
|
|
|
—
|
|
|
—
|
|
|
*%
|
|
Angelo P. Lopresti (8)
|
|
17,103,094
|
|
|
35,188
|
|
|
17,138,282
|
|
|
32.9
|
%
|
Timothy P.V. Mammen
|
|
16,736
|
|
|
49,063
|
|
|
65,799
|
|
|
*%
|
|
Alexander Ovtchinnikov, Ph.D. (8)
|
|
17,165,961
|
|
|
6,563
|
|
|
17,172,524
|
|
|
33.0
|
%
|
Trevor D. Ness
|
|
883
|
|
|
16,875
|
|
|
17,758
|
|
|
*%
|
|
Nikolai Platonov, Ph.D. (6)(8)
|
|
16,064,668
|
|
|
4,875
|
|
|
16,069,543
|
|
|
30.9
|
%
|
Felix Stukalin
|
|
316
|
|
|
10,688
|
|
|
11,004
|
|
|
*%
|
|
All executive officers and directors as a group
(14 persons)
|
|
18,762,097
|
|
|
310,488
|
|
|
19,072,585
|
|
|
36.5
|
%
|
*
|
Less than 1.0%
|
(1)
|
Includes 7,266,002 shares beneficially owned by IP Fibre Devices (UK) Ltd. (“IPFD”), in which the Valentin Gapontsev Trust I, a trust formed by Dr. Gapontsev (the “Gapontsev Trust I”), has a 48% economic interest. The trustees of the Gapontsev Trust I are Drs. Ovtchinnikov, Platonov and Scherbakov and Mr. Lopresti. Each of the individual trustees disclaims beneficial ownership of the shares held by the Gapontsev Trust I. See note 8 below.
|
(2)
|
Includes 7,266,002 shares beneficially owned by IPFD, of which Dr. Gapontsev is the sole managing director. Dr. Gapontsev has sole voting and investment power with respect to the shares held of record by IPFD. Dr. Gapontsev has a 3% economic interest in IPFD.
|
(3)
|
The address of Artisan Partners Limited Partnership is 875 East Wisconsin Avenue, Suite 800, Milwaukee, WI 53202. Based solely on a Schedule 13G/A filed with the SEC on March 24 , 2014.
|
(4)
|
The address of Columbia Wanger Asset Management, LLC is 227 West Monroe Street, Suite 3000, Chicago, IL 60606. Based solely on a Schedule 13G/A filed with the SEC on February 6, 2014.
|
(5)
|
These securities are owned by various individual and institutional investors which T. Rowe Price Associates, Inc. (“Price Associates”) serves as an investment advisor with power to direct investments and/or sole power to vote the securities. For the purposes of the reporting requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), Price Associates is deemed to be a beneficial owner of such securities; however, Price Associates expressly disclaims that it is, in fact, the beneficial owner of such securities. The address of T. Rowe Price Associates, Inc. is 100 E. Pratt Street, Baltimore, MD 21202. Based solely on a Schedule 13G filed with the SEC on February 12, 2014.
|
(6)
|
Does not include shares held by IPFD. Each such person has an 8% economic interest in IPFD but does not possess voting or investment power with respect to such interest. Each disclaims beneficial ownership of the shares held by IPFD except to the extent of his economic interest therein.
|
(7)
|
Includes 550,000 shares held by a trust of which Mr. Samartsev’s wife is the sole trustee. Mr. Samartsev disclaims beneficial ownership of the shares held in such trust.
|
(8)
|
Includes (a) 15,094,668 shares beneficially owned by the Gapontsev Trust I, (b) 970,000 shares beneficially owned by the Valentin Gapontsev Trust II, a trust formed by Dr. Gapontsev (the “Gapontsev Trust II”), and (c) 1,000,000 shares beneficially owned by the Valentin Gapontsev Trust III, a trust formed by Dr. Gapontsev (the “Gapontsev Trust III”), of each of which Drs. Ovtchinnikov and Scherbakov and Mr. Lopresti is a trustee. Dr. Platonov is a trustee of the Gapontsev Trust I and the Gapontsev Trust II and his beneficial ownership excludes shares beneficially owned by the Gapontsev Trust III.
|
Name
|
|
Age
|
|
Position
|
Valentin P. Gapontsev, Ph.D.
|
|
75
|
|
Chief Executive Officer and Chairman of the Board
|
Eugene Scherbakov, Ph.D.
|
|
66
|
|
Managing Director of IPG Laser GmbH, Senior Vice President, Europe and Director
|
Timothy P.V. Mammen
|
|
44
|
|
Chief Financial Officer and Senior Vice President
|
Angelo P. Lopresti
|
|
50
|
|
General Counsel, Secretary and Senior Vice President
|
Alexander Ovtchinnikov, Ph.D.
|
|
53
|
|
Senior Vice President, Components
|
Trevor D. Ness
|
|
41
|
|
Senior Vice President, World Wide Sales
|
Igor Samartsev
|
|
51
|
|
Chief Technology Officer and Director
|
Felix Stukalin
|
|
52
|
|
Senior Vice President, U.S. Operations
|
•
|
Valentin P. Gapontsev, Ph.D., our Chairman and Chief Executive Officer;
|
•
|
Timothy P.V. Mammen, our Senior Vice President and Chief Financial Officer;
|
•
|
Eugene Scherbakov, Ph.D., the Managing Director of IPG Laser GmbH, our subsidiary, and Senior Vice President, Europe;
|
•
|
Angelo P. Lopresti, our Senior Vice President, General Counsel and Secretary; and
|
•
|
Alexander Ovtchinnikov, Ph.D., our Senior Vice President, Components.
|
•
|
attract and retain talented and experienced executives;
|
•
|
motivate and reward executives whose knowledge, skills and performance are critical to achieving strategic business objectives;
|
•
|
align the interests of our executive officers and stockholders by motivating executive officers to increase long-term stockholder value;
|
•
|
provide incentives for future performance through both short-term and long-term financial incentives to build a sustainable company and foster the creation of stockholder value; and
|
•
|
foster a shared commitment among executives through establishment of uniform company goals.
|
•
|
In addition to a competitive base salary, a substantial portion of the executives’ potential cash compensation should be tied to a short-term incentive plan that rewards corporate and individual achievement of challenging performance goals; and
|
•
|
The Company uses a combination of restricted stock units and stock options with a service-based vesting to provide a combination of retention and motivation to increase the value of the Company’s common stock.
|
Compensation
Element
|
|
Objective
|
Base salary
|
|
Provide a competitive fixed component of cash compensation.
|
Short-term
incentive plan
|
|
Offer a variable cash compensation opportunity earned based upon the level of achievement of challenging corporate goals, with additional compensation opportunity based upon individual performance.
|
Long-term
incentives
|
|
Align long-term management and stockholder interests and strengthen retention with four-year vesting provisions. Service-based equity awards offer certainty and long-term retention while providing additional compensation opportunity to executives based upon increased stock price levels.
|
Benefit plans
|
|
Provide competitive employee benefits. We do not view this as a significant component of our executive compensation program.
|
•
|
comparable business (primarily laser, photonics, semiconductor, optical components and related device companies);
|
•
|
market capitalizations, annual revenue and employee levels; and
|
•
|
geographic location.
|
• II-VI Incorporated
|
|
• Analogic Corporation
|
|
• Brooks Automation, Inc.
|
• Chart Industries, Inc.
|
|
• Cognex Corporation
|
|
• Coherent, Inc.
|
• Cymer Inc.
|
|
• Diodes, Inc.
|
|
• Entegris, Inc.
|
• FEI Company
|
|
• FLIR Systems, Inc.
|
|
• Graco, Inc.
|
• Hittite Microwave Corporation
|
|
• MKS Instruments, Inc.
|
|
• Newport Corporation
|
• RBC Bearings, Inc.
|
|
• Rofin-Sinar Technologies Inc.
|
|
• Riverbed Technology, Inc.
|
• Teradyne, Inc.
|
|
• Veeco Instruments Inc.
|
|
|
2013 Short-Term Incentive Plan Payouts
|
||||||
Name
|
|
Target Awards ($)(1)
|
|
Actual Awards ($)
|
||
Valentin P. Gapontsev, Ph.D.
|
|
542,800
|
|
|
445,894
|
|
Timothy P.V. Mammen
|
|
261,224
|
|
|
219,402
|
|
Eugene Scherbakov, Ph.D.
|
|
299,092
|
|
|
246,462
|
|
Angelo P. Lopresti
|
|
249,321
|
|
|
209,405
|
|
Alexander Ovtchinnikov, Ph.D.
|
|
242,401
|
|
|
203,593
|
|
(1)
|
Target Awards include both financial and individual performance targets.
|
2013 Long-Term Equity-Based Incentive Grants
|
||||||
Name
|
|
Service-Based Stock
Options (#)
|
|
Service-Based
Restricted
Stock Units (#)
|
||
Valentin P. Gapontsev, Ph.D.
|
|
—
|
|
|
—
|
|
Timothy P.V. Mammen
|
|
14,200
|
|
|
2,200
|
|
Eugene Scherbakov, Ph.D.
|
|
13,000
|
|
|
2,000
|
|
Angelo P. Lopresti
|
|
11,000
|
|
|
1,800
|
|
Alexander Ovtchinnikov, Ph.D.
|
|
12,000
|
|
|
1,900
|
|
•
|
only the Compensation Committee has the authority to approve equity grants;
|
•
|
grants made by the Compensation Committee occur only after discussion at a meeting of the Compensation Committee;
|
•
|
equity award grants ordinarily are made by the Compensation Committee only during an open trading window period under our insider trading policy;
|
•
|
the grant date ordinarily is within ten business days following the first day of the open trading window period, or such other date as the Compensation Committee determines; and
|
•
|
the exercise price (if applicable) for all equity awards is the closing price of our stock on the date of grant and stock options are granted with an exercise price of no less than the closing price of our stock on the grant date.
|
Name and Principal Position
|
|
Year
|
|
Salary
($)
|
|
Bonus
($)
|
|
Stock
Awards
($)(1)
|
|
Option
Awards
($)(1)
|
|
Non-Equity
Incentive Plan
Compensation
($)(2)
|
|
All Other
Compensation
($)(3)
|
|
Total
($)
|
|||||||
Valentin P. Gapontsev, Ph.D.,
Chief Executive Officer and Chairman of the Board(4) |
|
2013
|
|
542,800
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
445,894
|
|
|
11,125
|
|
|
999,819
|
|
2012
|
|
475,822
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
369,850
|
|
|
12,345
|
|
|
858,017
|
|
||
2011
|
|
418,167
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
808,306
|
|
|
16,261
|
|
|
1,242,734
|
|
||
Timothy P.V. Mammen,
Chief Financial Officer and Senior Vice President |
|
2013
|
|
391,834
|
|
|
—
|
|
|
150,275
|
|
|
432,302
|
|
|
219,402
|
|
|
8,190
|
|
|
1,202,003
|
|
2012
|
|
340,101
|
|
|
—
|
|
|
120,233
|
|
|
353,768
|
|
|
177,993
|
|
|
8,040
|
|
|
1,000,135
|
|
||
2011
|
|
324,500
|
|
|
—
|
|
|
198,912
|
|
|
511,080
|
|
|
421,623
|
|
|
7,890
|
|
|
1,464,005
|
|
||
Eugene Scherbakov, Ph.D., Managing Director of IPG Laser and Director(4)
|
|
2013
|
|
432,777
|
|
|
—
|
|
|
132,242
|
|
|
403,482
|
|
|
246,462
|
|
|
33,677
|
|
|
1,248,640
|
|
2012
|
|
364,382
|
|
|
—
|
|
|
120,233
|
|
|
353,768
|
|
|
195,609
|
|
|
30,287
|
|
|
1,064,279
|
|
||
2011
|
|
376,187
|
|
|
—
|
|
|
176,602
|
|
|
449,561
|
|
|
488,452
|
|
|
32,576
|
|
|
1,523,378
|
|
||
Angelo P. Lopresti,
General Counsel, Secretary and Senior Vice President |
|
2013
|
|
373,980
|
|
|
—
|
|
|
120,220
|
|
|
374,662
|
|
|
209,404
|
|
|
8,892
|
|
|
1,087,158
|
|
2012
|
|
324,606
|
|
|
—
|
|
|
112,608
|
|
|
332,542
|
|
|
169,883
|
|
|
8,310
|
|
|
947,949
|
|
||
2011
|
|
309,750
|
|
|
31,997
|
|
|
176,602
|
|
|
449,561
|
|
|
402,458
|
|
|
8,160
|
|
|
1,378,528
|
|
||
Alexander Ovtchinnikov, Ph.D.,
Vice President —Components |
|
2013
|
|
363,600
|
|
|
—
|
|
|
108,198
|
|
|
345,842
|
|
|
203,593
|
|
|
8,892
|
|
|
1,030,125
|
|
2012
|
|
302,452
|
|
|
—
|
|
|
112,608
|
|
|
332,542
|
|
|
158,286
|
|
|
8,742
|
|
|
914,630
|
|
||
2011
|
|
288,750
|
|
|
—
|
|
|
176,602
|
|
|
449,561
|
|
|
375,173
|
|
|
8,592
|
|
|
1,298,678
|
|
(1)
|
Valuation based on the fair value of such award as of the grant date determined pursuant to ASC Topic 718. The assumptions that we used with respect to the valuation of restricted stock unit and stock option awards are set forth in Note 2 to our Consolidated Financial Statements in our Annual Report on Form 10-K filed with the SEC on
February 28, 2014
.
|
(2)
|
Represents amounts earned under our STIP for services rendered in
2013
,
2012
and
2011
, respectively.
|
(3)
|
The amount in
2013
for Dr. Gapontsev consists of
$11,125
in premiums paid for group term life insurance. Amounts for Messrs. Mammen and Lopresti and Dr. Ovtchinnikov include matching contributions to retirement accounts under our 401(k) plan and our payment of group term life insurance premiums. The amount for Dr. Scherbakov reflects the expense of an automobile provided by us.
|
(4)
|
Portions of the amounts paid to Dr. Gapontsev and Dr. Scherbakov were denominated in Euros and Rubles. These were translated into U.S. Dollars at the average daily exchange rates for the full years. The average daily rates in
2013
,
2012
and
2011
, for the Euro were 0.75, 0.78 and 0.72, respectively; and for the Ruble were 31.9, 31.17 and 29.29, respectively. As a result of compensation being paid in one or more currencies that fluctuate against the U.S. Dollar, the amount of salary paid may vary slightly from the salary stated in an employment agreement.
|
|
|
Grant
Date
|
|
Estimated Possible Payouts
Under Non-Equity Incentive
Plan Awards ($)(1)
|
|
All Other
Stock
Awards:
Number of
Shares of
Stock or
Units(#)(2)
|
|
Option
Awards
Number of
Securities
Underlying
Options
(#)(2)
|
|
Exercise or
Base Price
of Option
Awards
($ / Sh)
|
|
Grant Date
Fair Value
of
Stock and
Option
Awards
($)(3)
|
|||||||||||
Name
|
|
Threshold
|
|
Target
|
|
Maximum
|
|
||||||||||||||||
Valentin P. Gapontsev, Ph.D.
|
|
3/1/2013
|
|
101,775
|
|
|
407,100
|
|
|
1,221,300
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Timothy P.V. Mammen
|
|
3/1/2013
|
|
48,979
|
|
|
195,917
|
|
|
587,780
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3/1/2013
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,500
|
|
|
—
|
|
|
—
|
|
|
150,275
|
|
|
|
3/1/2013
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
15,000
|
|
|
60.11
|
|
|
432,302
|
|
|
Eugene Scherbakov, Ph.D.
|
|
3/1/2013
|
|
54,068
|
|
|
216,272
|
|
|
648,848
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3/1/2013
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,200
|
|
|
—
|
|
|
—
|
|
|
132,242
|
|
|
|
3/1/2013
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
14,000
|
|
|
60.11
|
|
|
403,482
|
|
|
Angelo P. Lopresti
|
|
3/1/2013
|
|
46,748
|
|
|
186,990
|
|
|
560,998
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3/1/2013
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,000
|
|
|
—
|
|
|
—
|
|
|
120,220
|
|
|
|
3/1/2013
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
|
13,000
|
|
|
60.11
|
|
|
374,662
|
|
||
Alexander Ovtchinnikov, Ph.D.
|
|
3/1/2013
|
|
45,450
|
|
|
181,800
|
|
|
545,427
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
3/1/2013
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,800
|
|
|
—
|
|
|
—
|
|
|
108,198
|
|
||
3/1/2013
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
12,000
|
|
|
60.11
|
|
|
345,842
|
|
(1)
|
Amounts shown represent potential amounts under the STIP for
2013
for achievement of financial performance measures, except that the possible payouts in the “Maximum” column represent the maximum permitted payout under the STIP for
2013
for both financial and individual performance measures. The performance goals used in determining STIP payments are discussed in the
Compensation Discussion and Analysis
above. Actual amounts paid for
2013
performance are shown in the “Non-Equity Incentive Plan Compensation” column in the Summary Compensation Table above.
|
(2)
|
The amounts listed reflect restricted stock units and stock options granted under our 2006 Incentive Compensation Plan and are described in the Outstanding Equity Awards Table below.
|
(3)
|
Valuation based upon the fair value of such award as of the grant date determined pursuant to ASC Topic 718. The assumptions that we used with respect to the valuation of restricted stock unit and stock option awards are set forth in Note 2 to our Consolidated Financial Statements in our Annual Report on Form 10-K filed with the SEC on
February 28, 2014
. The option exercise price has not been deducted from the amounts indicated above. Regardless of the value placed on a restricted stock unit or stock option on the grant date, the actual value of the restricted stock unit or stock option will depend on the market value of our common stock at such date in the future when the restricted stock unit vests or the stock option is exercised.
|
Name
|
|
Grant Date
|
|
Securities
Underlying
Unexercised
Options (#)
Exercisable
|
|
Securities
Underlying
Unexercised
Options (#)
Unexercisable
|
|
|
|
Option Exercise
Price ($)(1)
|
|
Option
Expiration
Date
|
|
Number
of Shares
or Units
of Stock
That
Have Not
Vested (#)
|
|
|
|
Market
Value of
Shares
or Units
of Stock
That
Have
Not
Vested
($)(2)
|
|||||||
Valentin P. Gapontsev, Ph.D.
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
|
—
|
|
Timothy P.V. Mammen
|
|
5/9/2008
|
|
|
25,000
|
|
|
—
|
|
|
|
|
19.69
|
|
|
5/8/2018
|
|
|
—
|
|
|
|
|
—
|
|
|
2/26/2009
|
|
|
17,500
|
|
|
—
|
|
|
|
|
8.26
|
|
|
2/25/2019
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
2/26/2010
|
|
|
—
|
|
|
26,250
|
|
|
(3)
|
|
15.82
|
|
|
2/25/2020
|
|
|
—
|
|
|
|
|
—
|
|
|
|
2/26/2010
|
|
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
4,375
|
|
|
(3)
|
|
339,544
|
|
|
|
3/1/2011
|
|
|
|
|
21,600
|
|
|
(4)
|
|
53.76
|
|
|
2/28/2021
|
|
|
—
|
|
|
|
|
|
||
|
|
3/1/2011
|
|
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
3,700
|
|
|
(4)
|
|
287,157
|
|
|
|
2/14/2012
|
|
|
—
|
|
|
12,500
|
|
|
(5)
|
|
58.65
|
|
|
2/13/2022
|
|
|
—
|
|
|
|
|
—
|
|
|
|
2/14/2012
|
|
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
2,050
|
|
|
(5)
|
|
159,101
|
|
|
|
3/1/2013
|
|
|
—
|
|
|
15,000
|
|
|
(6)
|
|
60.11
|
|
|
2/28/2023
|
|
|
—
|
|
|
|
|
—
|
|
|
|
3/1/2013
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
2/28/2023
|
|
|
2,500
|
|
|
(6)
|
|
194,025
|
|
|
Eugene Scherbakov, Ph.D.
|
|
2/26/2009
|
|
|
2,750
|
|
|
—
|
|
|
|
|
8.26
|
|
|
2/25/2019
|
|
|
—
|
|
|
|
|
—
|
|
|
2/26/2010
|
|
|
—
|
|
|
26,250
|
|
|
(3)
|
|
15.82
|
|
|
2/25/2020
|
|
|
—
|
|
|
|
|
—
|
|
|
|
2/26/2010
|
|
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
4,375
|
|
|
(3)
|
|
339,544
|
|
|
|
|
3/1/2011
|
|
|
|
|
19,000
|
|
|
(4)
|
|
53.76
|
|
|
2/28/2021
|
|
|
—
|
|
|
|
|
|
||
|
|
3/1/2011
|
|
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
3,285
|
|
|
(4)
|
|
254,949
|
|
|
|
2/14/2012
|
|
|
—
|
|
|
12,500
|
|
|
(5)
|
|
58.65
|
|
|
2/13/2022
|
|
|
—
|
|
|
|
|
—
|
|
|
|
2/14/2012
|
|
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
2,050
|
|
|
(5)
|
|
159,101
|
|
|
|
3/1/2013
|
|
|
—
|
|
|
14,000
|
|
|
(6)
|
|
60.11
|
|
|
2/28/2023
|
|
|
—
|
|
|
|
|
—
|
|
|
|
3/1/2013
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
2/28/2013
|
|
|
2,200
|
|
|
(6)
|
|
170,742
|
|
Name
|
|
Grant Date
|
|
Securities
Underlying
Unexercised
Options (#)
Exercisable
|
|
Securities
Underlying
Unexercised
Options (#)
Unexercisable
|
|
|
|
Option Exercise
Price ($)(1)
|
|
Option
Expiration
Date
|
|
Number
of Shares
or Units
of Stock
That
Have Not
Vested (#)
|
|
|
|
Market
Value of
Shares
or Units
of Stock
That
Have
Not
Vested
($)(2)
|
||||||||
Angelo P. Lopresti
|
|
5/9/2008
|
|
20,000
|
|
|
—
|
|
|
|
|
19.69
|
|
|
5/8/2018
|
|
|
—
|
|
|
|
|
—
|
|
||
|
2/26/2009
|
|
8,625
|
|
|
—
|
|
|
|
|
8.26
|
|
|
2/25/2019
|
|
|
—
|
|
|
|
|
—
|
|
|||
|
2/26/2010
|
|
—
|
|
|
26,250
|
|
|
(3
|
)
|
|
15.82
|
|
|
2/25/2020
|
|
|
—
|
|
|
|
|
—
|
|
||
|
|
2/26/2010
|
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
4,375
|
|
|
(3
|
)
|
|
339,544
|
|
|
|
|
3/1/2011
|
|
—
|
|
|
19,000
|
|
|
(4
|
)
|
|
53.76
|
|
|
2/28/2021
|
|
|
—
|
|
|
|
|
|
||
|
|
3/1/2011
|
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
3,285
|
|
|
(4
|
)
|
|
254,949
|
|
|
|
|
2/14/2012
|
|
—
|
|
|
11,750
|
|
|
(5
|
)
|
|
58.65
|
|
|
2/13/2022
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
2/14/2012
|
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
1,920
|
|
|
(5
|
)
|
|
149,011
|
|
|
|
|
3/1/2013
|
|
—
|
|
|
13,000
|
|
|
(6
|
)
|
|
60.11
|
|
|
2/28/2023
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
3/1/2013
|
|
|
|
|
|
|
|
|
|
2/28/2023
|
|
|
2,000
|
|
|
(6
|
)
|
|
155,220
|
|
||||
Alexander Ovtchinnikov, Ph.D.
|
|
2/26/2010
|
|
—
|
|
|
26,250
|
|
|
(3
|
)
|
|
15.82
|
|
|
2/25/2020
|
|
|
—
|
|
|
|
|
—
|
|
|
|
2/26/2010
|
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
4,375
|
|
|
(3
|
)
|
|
339,544
|
|
||
|
3/1/2011
|
|
—
|
|
|
19,000
|
|
|
(4
|
)
|
|
53.76
|
|
|
2/28/2021
|
|
|
—
|
|
|
|
|
—
|
|
||
|
|
3/1/2011
|
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
3,285
|
|
|
(4
|
)
|
|
254,949
|
|
|
|
|
2/14/2012
|
|
—
|
|
|
11,750
|
|
|
(5
|
)
|
|
58.65
|
|
|
2/13/2022
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
2/14/2012
|
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
1,920
|
|
|
(5
|
)
|
|
149,011
|
|
|
|
|
3/1/2013
|
|
—
|
|
|
12,000
|
|
|
(6
|
)
|
|
60.11
|
|
|
2/28/2023
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
3/1/2013
|
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
2/28/2023
|
|
|
1,800
|
|
|
(6
|
)
|
|
139,698
|
|
(1)
|
Represents the fair market value of a share of our common stock on the grant date.
|
(2)
|
Based upon the closing price of our common stock on
December 31, 2013
, which was
$77.61
per share.
|
(3)
|
Assuming the continued service of the Named Executive Officer, the options and restricted stock units vest in four equal quarterly installments commencing on March 31,
2014
.
|
(4)
|
Assuming the continued service of the Named Executive Officer, the options and restricted stock units vest in four equal quarterly installments commencing on March 31,
2015
.
|
(5)
|
Assuming the continued service of the Named Executive Officer, the options and restricted stock units vest in four equal quarterly installments commencing on March 31,
2016
.
|
(6)
|
Assuming the continued service of the Named Executive Officer, the options and restricted stock units vest in one installment on March 1,
2017
.
|
|
|
Option Awards
|
||||
Name
|
|
Number of Shares
Acquired on
Exercise (#)
|
|
Value Realized on
Exercise($)(1)
|
||
Valentin P. Gapontsev, Ph.D.
|
|
—
|
|
|
—
|
|
Timothy P.V. Mammen
|
|
35,448
|
|
|
1,961,076
|
|
Eugene Scherbakov, Ph.D.
|
|
36,378
|
|
|
1,955,298
|
|
Angelo P. Lopresti
|
|
22,000
|
|
|
1,327,068
|
|
Alexander Ovtchinnikov, Ph.D.
|
|
15,583
|
|
|
904,899
|
|
(1)
|
The value realized is based on the difference between the reported closing common stock price on the date of exercise and the exercise price of the stock option.
|
Name
|
|
Benefit
|
|
Termination
Without Cause or
For Good
Reason ($)(1)
|
|
Termination
Without Cause or
For Good
Reason
Following a
Change in
Control
($)(1)
|
||
Valentin P. Gapontsev, Ph.D.
|
|
Salary, Severance and Benefits Continuation
|
|
1,659,537
|
|
|
1,659,537
|
|
|
|
Incentive Plan Severance
|
|
1,221,300
|
|
|
2,912,138
|
|
|
|
Equity acceleration
|
|
—
|
|
|
—
|
|
|
|
Total
|
|
2,880,837
|
|
|
4,571,675
|
|
Timothy P.V. Mammen
|
|
Salary, Severance and Benefits Continuation
|
|
611,553
|
|
|
815,404
|
|
|
|
Incentive Plan Severance
|
|
587,780
|
|
|
1,184,191
|
|
|
|
Equity acceleration
|
|
1,961,531
|
|
|
3,422,449
|
|
|
|
Total
|
|
3,160,864
|
|
|
5,422,044
|
|
Eugene Scherbakov, Ph.D.
|
|
Salary, Severance and Benefits Continuation
|
|
656,379
|
|
|
875,171
|
|
|
|
Incentive Plan Severance
|
|
648,848
|
|
|
1,331,856
|
|
|
|
Equity acceleration
|
|
1,961,531
|
|
|
3,310,731
|
|
|
|
Total
|
|
3,266,758
|
|
|
5,517,758
|
|
Angelo P. Lopresti
|
|
Salary, Severance and Benefits Continuation
|
|
560,970
|
|
|
747,960
|
|
|
|
Incentive Plan Severance
|
|
560,998
|
|
|
1,157,409
|
|
|
|
Equity acceleration
|
|
1,961,531
|
|
|
3,268,921
|
|
|
|
Total
|
|
3,083,499
|
|
|
5,174,290
|
|
Alexander Ovtchinnikov, Ph.D.
|
|
Salary, Severance and Benefits Continuation
|
|
566,237
|
|
|
538,973
|
|
|
|
Incentive Plan Severance
|
|
545,427
|
|
|
1,123,655
|
|
|
|
Equity acceleration
|
|
1,961,531
|
|
|
3,251,421
|
|
|
|
Total
|
|
3,073,195
|
|
|
4,914,049
|
|
(1)
|
Equity acceleration is calculated using the full value of restricted stock units based upon the closing sale price of our common stock on
December 31, 2013
of
$77.61
per share and the aggregate difference between the exercise prices of stock options and the closing sale price of our common stock on
December 31, 2013
.
|
•
|
our compensation program is designed to provide a mix of both fixed and variable incentive compensation;
|
•
|
our senior executives are subject to stock ownership guidelines, which we believe incentivize our executives to consider the long-term interests of the Company and our stockholders and discourage excessive risk-taking that could negatively impact our stock price; and
|
•
|
our incentive compensation programs are designed with vesting terms that are relatively consistent, spread out over several years, and do not contain steep payout “cliffs” that might encourage short-term business decisions in order to meet a vesting or payout threshold.
|
•
|
any person becomes a beneficial owner of our securities representing at least 50% of the combined voting power of our then-outstanding securities;
|
•
|
persons who, at the beginning of any period of two consecutive years, were members of the Board of Directors cease to constitute a majority of the Board of Directors unless the election or nomination for election by the stockholders of each new director during that two-year period is approved by at least two-thirds of the incumbent directors then still in office;
|
•
|
the occurrence of a merger, sale of all or substantially all of our assets, cash tender or exchange offer, contested election or other business combination under circumstances in which our stockholders immediately prior to such merger or other such transaction do not, after such transaction, own shares representing at least a majority of our voting power or the surviving or resulting corporation, as the case may be; or
|
•
|
our stockholders approve a complete liquidation.
|
What We Do
|
|
What We Don’t Do
|
|
|
|
Align our Officer Pay with Performance:
Our Named Executive Officer compensation is tied to Company performance and stockholder returns. Performance drives pay.
|
|
No Retirement Benefits:
We have no supplemental executive retirement plans (SERPs) or defined benefit pension plans with any of our Named Executive Officers.
|
|
|
|
Balance Short-Term and Long-Term Incentives:
The incentive programs provide an appropriate balance of annual and long-term incentives and include multiple measures of performance.
|
|
No Tax Gross-Ups:
We do not provide tax gross reimbursements for change in control payments or executive perquisites, which are minimal.
|
|
|
|
Use Long-Term Incentives to Link Executive Pay to Company Performance:
35% of pay for our Named Executive Officers consists of long-term incentives linked to increasing our stock price. We conserve equity by not awarding long-term incentives to our Chief Executive Officer, the founder, whose interests are aligned with the stockholders. We have four-year cliff vesting for annual equity awards.
|
|
No Hedging and Limits on Pledging of Company Stock:
Our Named Executive Officers are prohibited from hedging their company stock. In 2013, we added a policy limiting the pledging of Company stock.
|
|
|
|
Cap Incentive Awards:
Short-term incentive plan awards are capped.
|
|
No Option Repricing without Stockholder Approval
|
|
|
|
Maximize Stockholder Value While Mitigating Risk:
Our equity incentives drive performance and reward growth over the long-term, which discourages short-term risk taking. The Committee reviews the Company's risk assessment.
|
|
No Single-Trigger Change in Control Provisions:
Our agreements do not make automatic payments to executives solely upon a change in control, i.e., no “single-trigger” arrangements.
|
|
|
|
Require Named Executive Officers to Maintain Stock Ownership:
All substantially exceed our ownership guidelines.
|
|
No Severance For "Cause" Terminations:
We do not pay severance for "cause" terminations.
|
|
|
|
Require Non-compete, Non-solicitation and Confidentiality Agreements:
We require executives to enter into non-competition, non-solicitation and confidentiality agreements as a condition of employment and as a condition of severance payments.
|
|
|
|
|
Fees
|
||||||||||
Fee Category
|
|
2013
|
|
2012
|
|
2011
|
||||||
Audit fees
|
|
$
|
1,197,733
|
|
|
$
|
1,086,580
|
|
|
$
|
1,016,013
|
|
Audit-related fees
|
|
$
|
37,000
|
|
|
146,200
|
|
|
24,000
|
|
||
Tax fees
|
|
$
|
200,000
|
|
|
7,500
|
|
|
—
|
|
||
Total Fees
|
|
$
|
1,434,733
|
|
|
$
|
1,240,280
|
|
|
$
|
1,040,013
|
|
|
|
|
|
|
IMPORTANT ANNUAL MEETING INFORMATION
|
|
|
|
|
Using a
black ink
pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas.
|
|
ý
|
|
|
|
|
|
•
|
Log on to the Internet and go to
|
•
|
Follow the steps outlined on the secured website.
|
|
|
|
Annual Meeting Proxy Card
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposals — The Board recommends a vote
FOR
all nominees and
FOR
Proposal 2.
|
|
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
1.
|
|
Election of Directors:
|
|
For
|
|
Withhold
|
|
|
|
For
|
|
Withhold
|
|
|
|
For
|
|
Withhold
|
|
+
|
|
|
01 - Valentin P.
Gapontsev, Ph.D.
|
|
¨
|
|
¨
|
|
02 - Eugene Scherbakov,
Ph.D.
|
|
¨
|
|
¨
|
|
03 - Igor Samartsev
|
|
¨
|
|
¨
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
04 - Robert A. Blair
|
|
¨
|
|
¨
|
|
05 - Michael C. Child
|
|
¨
|
|
¨
|
|
06 – Henry E. Gauthier
|
|
¨
|
|
¨
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
07 - William S. Hurley
|
|
¨
|
|
¨
|
|
08 - Eric Meurice
|
|
¨
|
|
¨
|
|
09 – John R. Peeler
|
|
¨
|
|
¨
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10 - Thomas J. Seifert
|
|
¨
|
|
¨
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
|
|
|
|
2.
|
|
To approve our executive compensation by non-binding advisory vote
|
|
¨
|
|
¨
|
|
¨
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
|
|
|
|
3.
|
|
To ratify the appointment of Deloitte & Touche LLP as the independent registered public
accounting firm of IPG Photonics Corporation for 2014.
|
|
¨
|
|
¨
|
|
¨
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change of Address
— Please print your new address below.
|
|
Comments
— Please print your comments below.
|
|
Meeting Attendance
Mark the box to the right if
you plan to attend the
Annual Meeting.
|
|
¨
|
||
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
C
|
|
Authorized Signatures — This section must be completed for your vote to be counted. — Date and Sign Below
|
|
|
|
|
|
|
|
|
|
Date (mm/dd/yyyy) — Please print date below.
|
|
Signature 1 — Please keep signature within
the box.
|
|
|
|
Signature 2 — Please keep signature
within the box.
|
||
/ /
|
|
|
|
|
|
|
|
|
|
|
|
|
|
¢
|
|
|
|
+
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|
No information found
Customers
Customer name | Ticker |
---|---|
Medtronic plc | MDT |
Thermo Fisher Scientific Inc. | TMO |
No Suppliers Found
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|